Evidence map›Paper›PMID 42703582›Full record

ArticleFrontiers in pharmacology2026

Low-dose sulbactam-durlobactam for recurrent CRAB pneumonia in a child with cerebral palsy: a Case Report from a resource-limited setting.

Mengting Li, Haotian Fei, Liang Huang, Lu Qing, Xiaoliang Liu, Guoyan Lu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mengting LiDepartment of Pediatrics, Ministry of Education Key Laboratory of Women and Children's Diseases and Birth Defects, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Haotian FeiDepartment of Pediatrics, Ministry of Education Key Laboratory of Women and Children's Diseases and Birth Defects, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Liang HuangDepartment of Pediatrics, Ministry of Education Key Laboratory of Women and Children's Diseases and Birth Defects, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Lu QingDepartment of Pediatrics, Ministry of Education Key Laboratory of Women and Children's Diseases and Birth Defects, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Xiaoliang LiuDepartment of Pediatrics, Ministry of Education Key Laboratory of Women and Children's Diseases and Birth Defects, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Guoyan LuDepartment of Pediatrics, Ministry of Education Key Laboratory of Women and Children's Diseases and Birth Defects, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pediatric data for sulbactam-durlobactam (SUL-DUR) are extremely scarce, and no standard pediatric dosing exists. Methods: We report a 6-year-old boy with cerebral palsy and epilepsy who developed recurrent ventilator-associated pneumonia caused by OXA-23-producing carbapenem-resistant Results: Due to financial constraints, a reduced-dose SUL-DUR regimen (150 mg/kg/day, q6h, 3-h infusion) was combined with cefoperazone-sulbactam to achieve a total sulbactam dose of 150 mg/kg/day. The patient defervesced within 48 h, inflammatory markers declined, chest imaging improved markedly, and he was transferred out of the PICU after 12 days of therapy. Conclusion: A PK/PD-driven low-dose SUL-DUR strategy may represent a feasible and potential cost-saving strategy for pediatric CRAB pneumonia in resource-limited settings.

Indexed as

carbapenem-resistant Acinetobacter baumanniilow-dose regimenOXA-23pediatric pneumoniaresource-limited settingsulbactam-durlobactam

Identifiers

PMID42703582
PMCPMC13546741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.